Cibisatamab (Not yet branded)

Description

Cibisatamab is a bispecific T-cell engager (BiTE) antibody designed to simultaneously bind to CEA (carcinoembryonic antigen) on cancer cells and CD3 on T-cells. In colorectal cancer treatment, it is being evaluated specifically in microsatellite stable (MSS) tumors, which typically respond poorly to conventional immunotherapy. The drug is formulated to redirect the patient's own T-cells to attack CEA-expressing colorectal cancer cells through direct cellular contact.

Mechanism of Action

Cibisatamab functions as a bispecific antibody that creates an immunological synapse between cytotoxic T-lymphocytes and CEA-positive tumor cells. By binding CD3 on T-cells and CEA on colorectal cancer cells simultaneously, it bypasses the need for traditional T-cell activation pathways and directly triggers T-cell mediated cytotoxicity against the tumor. This mechanism is particularly relevant for MSS colorectal cancers, which lack the high mutational burden needed for effective checkpoint inhibitor response.

Molecular Targets

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials